Advertisement

Checkpoint inhibitor-induced uveitis: a case series

  • Christopher D. Conrady
  • Marissa Larochelle
  • Paula Pecen
  • Alan Palestine
  • Akbar Shakoor
  • Ajay SinghEmail author
Inflammatory Disorders

Abstract

Purpose

Checkpoint inhibitors are now a common treatment modality for metastatic cancer. In this manuscript, we describe the clinical features and management of autoimmune non-infectious uveitis induced by this class of drugs.

Methods

Seven patients undergoing checkpoint inhibitor treatment for metastatic cancer from uveitis practices at three tertiary referral centers.

Results

All seven patients developed various severities of ocular inflammatory disease while taking checkpoint inhibitors for metastatic disease.

Conclusions

Checkpoint inhibitors may induce autoimmune uveitis. Ocular complaints should prompt an early evaluation by an ophthalmologist.

Keywords

Checkpoint inhibitors Metastatic cancer Autoimmune uveitis 

Notes

Funding

Research to Prevent Blindness, Inc., New York, NY, provided an unrestricted grant to the to the Department of Ophthalmology & Visual Sciences at the University of Utah and to the Department of Ophthalmology, University of Colorado. The sponsor had no role in the design of this study.

Compliance with ethical standards

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (institutional review board) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this retrospective study formal consent is not required.

Supplementary material

417_2017_3835_Fig3_ESM.gif (167 kb)
Supplemental Figure 1

Nivolumab-associated VKH-like syndrome: Case 5. A 52-year-old man with metastatic melanoma being treated with nivolumab, and who had recently discontinued ipilimumab per treatment protocol, developed a cloud in the vision of his right eye, whitening of his eyebrows, several patches of skin depigmentation, and hearing loss. ab Fundus photographs showed optic disc edema, OD > OS and loss of foveal light reflex OD. cd OCT identified subretinal fluid in the right eye (c) and normal retinal architecture of the left (d), with resolution of subretinal fluid with oral prednisone (e). (GIF 167 kb)

417_2017_3835_MOESM1_ESM.tif (10.7 mb)
High Resolution (TIFF 10945 kb)
417_2017_3835_Fig4_ESM.gif (365 kb)
Supplemental Figure 2

Nivolumab-associated multifocal choroiditis: Case 6. A 57-year-old man with metastatic non-small cell adenocarcinoma of the lung that was being treated with nivolumab infusions developed conjunctival injection, decreased vision, and photosensitivity OU approximately 9 months after starting therapy. ab At presentation, the patient had anterior uveitis, subretinal fluid extending from the nerve, an irregular choroid, and disc leakage and patchy hyperfluorescence of the posterior pole. cd Enhanced-depth imaging OCT OD revealed a thickened choroid, indicated by yellow arrows, and repeat OCT showed subfoveal subretinal fluid. ef Fundus photographs several months after initial presentation demonstrated depigmented chorioretinal lesions in both eyes despite a negative HLA-A29. This was consistent with a multifocal choroiditis that was not evident at presentation (eg), but showed resolution of choroidal thickening, indicated by the yellow arrows. (GIF 365 kb)

417_2017_3835_MOESM2_ESM.tif (28.1 mb)
High Resolution (TIFF 28818 kb)
417_2017_3835_Fig5_ESM.gif (104 kb)
Supplemental Figure 3

Pembrolizumab-associated iridocyclitis: Case 7. A 62-year-old man with metastatic melanoma treated with dabrafenib and trametinib discontinued both medications 1 week prior to presentation due to blurry vision with fevers, chills, and rash. Macular edema was noted on exam and confirmed by OCT, and improved with local steroids. After restarting his immunostimulatory medications, he developed iritis, keratic precipitates, AC cell, and macular edema controlled with local therapy. Four months after initial presentation, the patient changed treatment from dabrafenib and trametinib to pembrolizumab, but continued to have intermittent episodes of iridocyclitis and cystoid macular edema (above) controlled with local therapy. (GIF 104 kb)

417_2017_3835_MOESM3_ESM.tif (13.7 mb)
High Resolution (TIFF 14034 kb)

References

  1. 1.
    Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985–988CrossRefPubMedGoogle Scholar
  2. 2.
    Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001) Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319–322.  https://doi.org/10.1126/science.291.5502.319 CrossRefPubMedGoogle Scholar
  3. 3.
    Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727.  https://doi.org/10.1038/nri1936 CrossRefPubMedGoogle Scholar
  4. 4.
    Pauken KE, Wherry EJ (2015) Overcoming T cell exhaustion in infection and cancer. Trends Immunol 36:265–276.  https://doi.org/10.1016/j.it.2015.02.008 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793–800.  https://doi.org/10.1038/nm730 CrossRefPubMedGoogle Scholar
  6. 6.
    Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO (2007) Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 13:84–88.  https://doi.org/10.1038/nm1517 CrossRefPubMedGoogle Scholar
  7. 7.
    Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252–264.  https://doi.org/10.1038/nrc3239 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Mandala M, De Logu F, Merelli B, Nassini R, Massi D (2017) Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. Lab Investig 97:166–175.  https://doi.org/10.1038/labinvest.2016.132 CrossRefPubMedGoogle Scholar
  9. 9.
    Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7:122–136.  https://doi.org/10.1177/1758834014566428 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Draganova D, Kerger J, Caspers L, Willermain F (2015) Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthal Inflamm Infect 5:17.  https://doi.org/10.1186/s12348-015-0049-9 CrossRefGoogle Scholar
  11. 11.
    Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282:2263–2266CrossRefPubMedGoogle Scholar
  12. 12.
    Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB, Pistillo MP (2005) CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538–550.  https://doi.org/10.1002/ijc.21155 CrossRefPubMedGoogle Scholar
  13. 13.
    Wolchok JD, Saenger Y (2008) The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 Suppl 4:2–9.  https://doi.org/10.1634/theoncologist.13-S4-2 CrossRefPubMedGoogle Scholar
  14. 14.
    Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372–8377.  https://doi.org/10.1073/pnas.1533209100 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Karlin J, Gentzler R, Golen J (2016) Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm 1–3.  https://doi.org/10.1080/09273948.2016.1215473
  16. 16.
    Aaberg MT, Aaberg TM Jr (2016) Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep.  https://doi.org/10.1097/ICB.0000000000000368
  17. 17.
    Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM (2015) New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 50:e2–e4.  https://doi.org/10.1016/j.jcjo.2014.10.010 CrossRefPubMedGoogle Scholar
  18. 18.
    Kahloun R, Mbarek S, Khairallah-Ksiaa I, Jelliti B, Yahia SB, Khairallah M (2013) Branch retinal artery occlusion associated with posterior uveitis. J Ophthal Inflamm Infect 3:16.  https://doi.org/10.1186/1869-5760-3-16 CrossRefGoogle Scholar
  19. 19.
    Linardou H, Gogas H (2016) Toxicity management of immunotherapy for patients with metastatic melanoma. Ann Transl Med 4:272.  10.21037/atm.2016.07.10 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Maezawa N, Yano A (1984) Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol Immunol 28:219–231CrossRefPubMedGoogle Scholar
  21. 21.
    Caspi RR (2010) A look at autoimmunity and inflammation in the eye. J Clin Invest 120:3073–3083.  https://doi.org/10.1172/JCI42440 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Choe CH, McArthur GA, Caro I, Kempen JH, Amaravadi RK (2014) Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 158:831–837.e832.  https://doi.org/10.1016/j.ajo.2014.07.003 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Christopher D. Conrady
    • 1
  • Marissa Larochelle
    • 1
  • Paula Pecen
    • 2
  • Alan Palestine
    • 2
  • Akbar Shakoor
    • 1
  • Ajay Singh
    • 3
    Email author
  1. 1.Department of Ophthalmology, John A. Moran Eye CenterUniversity of UtahSalt Lake CityUSA
  2. 2.Department of OphthalmologyUniversity of Colorado School of MedicineAuroraUSA
  3. 3.Department of OphthalmologyUniversity of Kansas School of MedicineKansas CityUSA

Personalised recommendations